Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome Inc (IMNM) is a clinical-stage biopharmaceutical company advancing novel antibody therapies for cancer and infectious diseases through its proprietary human memory B cell platform. This page serves as the definitive source for verified corporate announcements, research milestones, and financial disclosures.
Investors and industry professionals will find timely updates on clinical trial progress, strategic collaborations like the Nectin Therapeutics partnership, and regulatory developments. Our curated news collection enables efficient tracking of Immunome's expanding oncology pipeline and infectious disease programs.
Key content categories include therapy development updates, intellectual property announcements, executive leadership changes, and quarterly financial results. All materials are sourced from official company communications and vetted industry reports.
Bookmark this page for streamlined access to Immunome's latest scientific advancements and business developments. For comprehensive analysis of IMNM stock performance, visit Stock Titan's dedicated market data section.
Immunome (NASDAQ: IMNM) has successfully closed its upsized public offering, selling 22,258,064 shares of common stock at $7.75 per share, including the full exercise of underwriters' option to purchase an additional 2,903,225 shares. The offering generated gross proceeds of $172.5 million before deducting underwriting discounts, commissions, and expenses.
The offering was managed by multiple financial institutions, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities acting as joint book-running managers, while Wedbush PacGrow served as lead manager. The offering was conducted under a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.
Immunome (Nasdaq: IMNM) has announced the pricing of an upsized public offering of 19,354,839 shares of common stock at $7.75 per share. The company expects to raise gross proceeds of $150.0 million before deducting underwriting discounts and expenses.
The offering includes a 30-day option for underwriters to purchase up to an additional 2,903,225 shares at the public offering price. The offering is expected to close on January 31, 2025. J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers, with Wedbush PacGrow as lead manager.
Immunome (NASDAQ: IMNM) has announced plans for an underwritten public offering of $125.0 million worth of common stock shares. The biotechnology company, focused on developing first-in-class and best-in-class targeted cancer therapies, will grant underwriters a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
The offering will be managed by joint book-running managers J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities, with Wedbush PacGrow acting as lead manager. The offering is being made through a shelf registration statement on Form S-3 filed with the SEC on February 13, 2024.
Immunome (NASDAQ: IMNM) announced key pipeline updates ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company expects topline data from the Phase 3 RINGSIDE study of varegacestat, a daily oral gamma secretase inhibitor for desmoid tumors, in H2 2025.
The FDA has cleared the IND for IM-1021, a ROR1-targeted ADC, in Q4 2024. The company plans to submit an IND for IM-3050, a FAP-targeted radioligand therapy, by Q1 2025. Additionally, three novel ADC programs for solid tumors - IM-1617, IM-1340, and IM-1335 - are advancing in preclinical development.
Immunome (NASDAQ: IMNM) announced that its Compensation Committee granted inducement awards to four new employees on January 2, 2025. The awards consist of non-statutory stock options to purchase a total of 45,000 shares of common stock under the Company's 2024 Inducement Plan.
The stock options have an exercise price of $10.53 per share, matching the Company's closing price on January 2, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome announced that its Compensation Committee granted inducement awards of non-statutory stock options to 15 new employees under the Company's 2024 Inducement Plan. The options allow purchase of 210,500 shares at $14.08 per share, based on the closing price on December 2, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, December 3, 2024, at 4:30 p.m. Eastern time.
A live audio webcast will be accessible through the Investor Relations section of Immunome's website. Following the presentation, a replay will remain available for approximately 30 days.
Immunome (Nasdaq: IMNM) announced its Q3 2024 financial results and provided a business update. The company reported a net loss of $47.1 million for the quarter ended September 30, 2024, with cash, cash equivalents, and marketable securities totaling $240.1 million, providing a cash runway into 2026. R&D expenses were $37.2 million, and G&A expenses were $9.5 million. Key pipeline updates include the completion of full enrollment for the Phase 3 RINGSIDE Part B study of AL102 for desmoid tumors, with topline data expected in H2 2025. IND submissions for IM-1021 and IM-3050 are anticipated in Q1 2025. The discovery team is focused on discovering ADCs targeting novel cancer therapy targets, highlighting the potential of HC74, a proprietary TOP1 payload.
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. Clay Siegall, PhD, President and CEO, will engage in a fireside chat on Wednesday, November 13th at 10:30am Eastern Time. The presentation will be accessible via live audio webcast through the company's website's Investor Relations section, with a replay available for approximately 30 days post-event.
Immunome (Nasdaq: IMNM) announced that its Compensation Committee granted inducement awards to 14 new employees on October 31, 2024. The awards consist of non-statutory stock options to purchase 378,800 shares of common stock under the Company's 2024 Inducement Plan. The options have an exercise price of $11.47 per share, matching the Company's closing price on October 31. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
